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Abstract: 
The drug ethambutol HCl is one of the first line antitubercular agent available in tablet form 
used in the treatment of pulmonary tuberculosis disease, for long term therapy but according to 
researcher the drug shows poor absorptivity in presence of food when administered orally & 
required higher dose of about 25mg/kg, also has short half life i.e.2-4 hrs., so to well utilization 
of drug as well as to minimize the side effects, there should have to modify the formulation in 
other suitable dosage form, like vesicular drug delivery system, in which incorporating the drug 
into system in the form of niosomes, and its characteristic action gives the sustained release of 
dose. So the present work of this research was to prepared and evaluate the niosomal drug 
delivery system by reverse phase evaporation method and were evaluated their particle size 
analysis, surface morphology, entrapment efficiency, in-vitro release profile etc. 
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INTRODUCTION: 
For proper delivering of drug to the site of action 
with the aim of sustained and prolonged effect of 
medication, there is a number of drug delivery 
systems are available in medical science like that 
vesicular delivery system is one of them. It is 
preferred due to the presence of lipid vesicles in its 
structure which support as carrier system and such 
vesicles have some value in membrane biology, 
immunology and diagnostic technique as well in 
genetic engineering,to incorporate both lipophilic as 
well as hydrophilic drug for long term activity, leads 
to reduction of drug intake by improving 
bioavailability of medication,cause least side 
effects.There is number of lipid based vesicular drug 
delivery systems like virosomes, cubosomes, 
liposomes, niosomes, ethosomes, transferosomes etc. 
are available. Such delivery systems are used to delay 
drug elimination, complete metabolized drug and 
gives sustained activity with solves the instability, 
insolubility, rapid degradation problems and widely 
used in specialized areas like gene delivery, protein 
delivery, tumor targeting and  targeting to brain etc 
[1,2]. 
 
Niosomes 
These are type of vesicular drug delivery system, in 
which the specified medication is incorporated in a 
vesicle. The vesicle is composed of a bilayer of non-
ionic surface active agent is known as niosomes. 
These are very small and microscopic in size also lies 
in the nanometric scale, structurally similar to 
liposomes, niosomes are mostly formed by 
incorporation of cholesterol with excipients, and 
these are more penetrating power than any emulsions 
[3]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1: Structure of Niosomes 
 
 
The above image of niosomes are shows lamellar 
structures, hydrophilic nonionic surfactant point 
outwards and hydrophobic ends face each other to 
form bilayer, constitute of stability based non-ionic 
surfactant polyoxyethylene ether class and 
cholesterol in aqueous medium. In generally the 
vesicular drug delivery system is mainly affected by 
type of surfactant used, nature of drug, temperature 
and use of lipids etc [4]. 
Advantage of Niosomes 
 Due to water–based vehicle, niosomes offers 
high patient compliance compared to oily 
dosage forms. 
 Due to presence of hydrophilic, amphiphilic 
and lipophilic moieties in its structurewhich 
facilitates drug incorporation as well as 
protectionto target the site of action in 
controlled as well sustained manner. 
 Niosomes can modify the metabolic rate and 
half life of the drug, thus decreasing the side 
effects of the drugs by improving the 
bioavailability of poorly dissolved drugs [5]. 
Disadvantages of Niosomes  
 Physically instable 
  Aggregation 
  Fusion 
  Leakage of entrapped drug  
 Due to hydrolysis of encapsulated drug 
limits the shelf-life of the dispersion. 
Application of Niosomes 
 Niosomes used as carriers for deliver drugs, 
hormones, vaccines at the site of action. 
 As penetration enhancers, for systemic 
absorption of drugs through skin. 
 Used to target drugs to the 
reticuloendothelial system.  
 To treat tumors in animals, parasitic 
infections of the liver.  
 Niosomes used to protect the peptides from 
gastrointestinal peptide breakdown. 
 Due to their immune selectivity, low 
toxicity, good stability they are used to study 
the nature of the immune response provoked 
by antigens [6]. 
Tuberculosis 
As the population increases there is number of 
diseases also increases in the world due to 
environmental pollution, improper cleanliness 
likewise diseases like Tuberculosis (TB) is one of 
them, itis an airborne infectious disease caused by 
organism mycobacterium tuberculosis,Which is 
generated by the coughing, sneezing, talking, or 
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singing of a person with pulmonary or laryngeal 
tuberculosis and spread by small airborne droplets 
[7], which affects the respiratory system as well as 
other organs like lymph node, pleura, bone, genitor 
urinary tract etc. which caused by number of death in 
the developing world. According to the World Health 
Organization one third of the world’s population is 
suffered with Mycobacterium tuberculosis [8,9]. 
Types of Tuberculosis: 
Based on clinical manifestation after exposure and 
location of bacilli. 
1. Primary infection: When infected droplet 
enters in the terminal of alveoli of lungs of the 
body, it shows first exposure to tubercle bacilli, 
and begins life cycle of bacilli in the lungs. 
2. Secondary infection: It is occurs re-entry of 
organisms who is already hypersensitive due to 
earlier exposure [10]. 
For tuberculosis therapy there is number of drugs are 
available those are classified into two types- 
1. First line drug: eg.- Isoniazid, Rifampin, 
Pyrazinamide, Ethambutol, Streptomycin 
2. Second line drug: eg. - Thiacetazone, 
Paraaminosalicylic acid, Ethionamide, Cycloserine, 
Kanamycin [11]. 
Currently Available treatment for tuberculosis: 
Treatment of active tuberculosis with a single drug is 
notpossible andthis result may development of 
tuberculosis, as suggested by WHO treatment of TB 
requires multi-drug therapy and comprising of, 
1) Beginning intensive phase of rifampicin (RIF), 
isoniazid (INH), pyrazinamide (PYZ), and 
ethambutol (ETB) daily for two months. 
2) A continuation phase of RIF and INH for a 
further four months, either daily or 3 times per 
week, to be taken as per advise [12]. 
According to researcher, tuberculosis therapy is more 
difficult, due to the randomized structure and 
chemical composition of cell wall of mycobacterium 
organism, so the use of most antibiotics is ineffective. 
In actual TB requires long period treatment (around 6 
to 24 months) to entirely eliminate mycobacteria 
from the body, almost all antitubercular drug shows 
poor absorption in presence of food and therapy may 
need long term. Sometimes poor patient compliance 
is the common reason for failure of TB therapy, these 
problems can be prevented by loading the drug by 
lipid coating. The lipid coating is destabilized when 
interaction with target cells, w h i c h  results in the 
local release of the encapsulated drug such system is 
known asvesicular drug delivery system. 
MATERIALS AND METHODOLOGY: 
Materials: 
Ethambutol Hcl, Polyoxyethylene (2) stearyl ether 
(Brij 72), Stearyl amine, Cholesterol, Potassium 
dihydrogen phosphate, Disodium hydrogen 
phosphate, Sodium chloride, Chloroform etc. 
Preparation of Blank Niosomes [13] 
To optimize the processing condition, excipients like 
Cholesterol and surfactant are dissolved in a mixture 
of ether and chloroform (1:1), thus a blank niosomes 
was prepared.  
Preparation of Ethambutol HCl loaded Niosomes. 
The comparative study formulation chart for 
Niosomes preparation is shown in following table. 
Niosomes of Ethambutol HCl prepared by Reverse 
phase evaporation method (REV), An aqueous phase 
(about 25ml) containing drug (100 mg) is added to 
prepared blank niosomes and the resulting two phases 
are sonicated at less temperature, by probe sonication 
by addition of a phosphate buffered saline (PBS) 
solution which form clear gel.Further niosomal 
suspension was diluted with PBS and stir for 10min 
to yield niosomes. The present organic phase was 
removed by rotary evaporator by applying suitable 
temperature. 
 
Table  1: Formulation Table of Ethambutol Hydrochloride loaded Niosomes 
Formulation Drug(mg) Cholesterol (mg) Brij 72 (mg) Stearyl amine (mg) 
F1 100 500 400 4 
F2 100 250 200 2 
F3 100 250 400 2 
F4 100 500 200 4 
F5 100 500 400 2 
F6 100 500 200 2 
F7 100 250 400 4 
F8 100 250 200 4 
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Evaluation and Characterization 
Preformulation Studies: 
The drug morphological, melting point, solubility 
studies.  
Reverse Phase (RP) HPLC studies:  
Analysis of drug by RP- HPLC method for 
standardization of maximum wavelength by 
obtaining standard calibration curve. 
Drug Excipients Physical Compatibility Study 
(FTIR) 
The active drug nature and drug-excipients 
compatibility study was done prior to the formulation 
of niosomes by Fourier transform infra-red (FTIR) by 
comparing spectral peaks in the spectra of 
Ethambutol drug and excipientswith standard 
reference spectra. 
Differential Scanning Calorimetry (DSC)  
DSC is one of the most used calorimetric techniques, 
employed to characterize the solubility and physical 
state of drug in the complex. Thermo grams of 
ethambutol HCl and one formulation of ethambutol 
HCl loaded niosomes was recorded using a DSC and 
were compared. The samples (5 mg) were 
hermetically sealed in flat bottomed aluminum pans 
and heated at a temperature of 100-300 °C using 
alumina as a reference standard. 
Particle Size and Surface Morphology Analysis: 
Particle size and surfacemorphological study 
wasanalyzedbyscanningelectronmicroscopy(SEM). 
Here,  the cleaned brass specimen studs were used 
for sample mounting. Then wet solvent paint was 
applied on these studs and as the paint was wet, the 
pellets were placed on each stud and allowed for dry. 
Then the sample was observed in SEM and 
photographs were taken. 
Determination of Percentage of Entrapment 
Efficiency (E.E): 
Entrapment efficiency of Ethambutol HCl loaded 
niosoms was done by centrifugationmethod. The 
niosomalpreparationwere placed in centrifugation 
tube and applied 15000 rpm, for 30 min. The 
supernatant (1ml) content was taken and diluted with 
water. Then the unentrapped drug was determined by 
UV spectrophotometer at 360 nm. The free 
ethambutol HCl in the supernatant gives the total 
amount of unentrapped drug, and encapsulation 
efficiency is known as the percent of drug trapped 
and was calculated by following equation. Drug 
content was calculated from equation of straight line 
obtained for standard curve for ethambutol HCl. 
Total amount of drug – Free dissolved drug 
% E.E = ----------------------------------------------------------X   100 
Total amount of drug. 
In vitro Drug Release Studies [14,15] 
The in vitro drug release profile is an important tool 
that predicts in advance how a drug may behave in 
vivo. Release studies are required to predict the 
reproducibility of rate and duration of drug release.  
Drug release 
To determine the invitro drug release kinetics of 
niosomes, the dialysis method is used. Prepared 
niosomal content was placed in the dialysis pouch 
and sealed, then place the pouch in 200ml of buffer 
solution with constant stirring at 37 ºC. Samples were 
withdrawn at regular interval and drug content 
analysis is carried out by UV visible spectroscopical 
method. 
Release kinetics 
The data of In-vitrorelease study was fitted in to three 
different kinetics models namely zero order, first 
order, and higuchi’s classical model. The drug release 
mechanism is defined statics in terms of co-relation 
co-efficient, the highest values of co-relation co-
efficient shows the appropriate release mechanism. 
RESULTS AND DISCUSSION: 
Preformulation Studies: 
The sample of Ethambutol HCl was found to bewhite 
to off white, odourless powder. And based on 
literature, the melting point of Ethambutol  
HClis200-202oC, and by estimation it was found to 
be 196- 203oC that  indication isdrug purity.And was 
soluble in water and slightly soluble in methanol. 
HPLC analysis for Determination of λ max: 
The λ max of Ethambutol HCl was determined in 
water by RP-HPLC, It was found to be maximum 
wavelength 415nm. And the same shown in figure 
no. 2. 
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Fig  2: λ max of ethambutol HCl 
Standard calibration curve for Ethambutol HCl in 
water. 
Calibration curve for Ethambutol HCl was 
constructed using water as solvent at 415nm.The 
concentration selected was 10-50µ/ml. and data of 
calibration observed in table no. 2, with graphical 
representation in figure no. 3 
Table  2:  Calibration data for Ethambutol HCl 
Concentration µg/ml Absorbance* 
10 0.093 
20 0.172 
30 0.280 
40 0.365 
50 0.430 
 
 
Fig 3: Standard calibration Curve of Ethambutol HCl 
A straight line was obtained at R2=0.997. Equation of straight was found to be y= 0.008 x -0.001 
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FTIR study 
By FTIR study of ethambutol HCl, it was found to be 
the obtained spectral peaksof functional group 
present in drug were compared with standard 
reference peaks and found that drug is pure one. The 
obtained FTIR spectra of drug are shown in fig.no.4 
and respective functional group shown in table no.3. 
As well asthe obtained spectral peaks of functional 
group present in mixture of drug with brij 72 and 
cholesterol were compared with standard reference 
peaks and found that drug was miscible throughout 
the mixture. Obtained FTIR spectra of mixture of 
drug with excipients are shown in figure no. 5 and 
respective spectral functional group shown in table 
no.4  
  
 
Fig.4: IR Spectra of Pure Ethambutol HCl 
Table 3: Peaks (Cm-1) and Functional Groups Present Ethambutol HCl. 
Sr. No. Peaks cm-1 Functional group 
1 2881.65 C-H (CH3) 
2 1350.17 O-H (Stre) 
3 3280.92 N-H (Sed) 
4 1529.55 C-H (def) 
 
 
Fig 5: IR of mixture of Ethambutol HCl + Brij 72+Cholesterol. 
Table 4: Peaks (Cm-1) and Functional Groups Present in mixture of Ethambutol HCl + Brij72 + Cholesterol 
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Figure no. 6: IR Spectra of Ethambutol HCl loaded Niosomes Formulation 
  Table no.5:  Peaks (Cm-1) and Functional Groups Present Niosomes formulation  
Sr. No. Peaks cm-1 Functional group 
1  3352.11 C-H(CH3) 
2           1636.78 C-H (Str) 
 
FTIR gives thespectral peaks of ethambutol loaded 
niosomal formulation were compared with standard 
reference spectral peaks of functional group and 
found that the drug pure and is compatible with 
excipients which are used in formulation. Obtained 
FTIR spectra of drug loaded niosomes are shown in 
figure no.6 with respective functional group shown in 
table no.5. 
Differential Scanning Calorimetry (DSC) 
Using DSC analysis of drug, polymer and excipients 
the nature of the drug inside the polymer matrix can 
be assessed. The obtained DSC graph of formulation 
is shown in figure no. 7 
Sr. No. Peaks cm-1 Functional group 
1 2883.58 C-H 
2 1350.17 O-H (Str) 
3 3275.13 N-H (Sed) 
4 1523.76 C-H (Def) 
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Fig 7 : DSC Thermogram Of Ethambutol Hcl Pure Drug 
The DSC patterns of pure ethambutol shown a sharp 
endotherm at 202.55 °C with corresponding to its 
melting point. So there was a negligible change in the 
melting endotherms ofthe formulation compared to 
pure drug. This observation further supports the IR 
spectroscopy results, which shows the absence of 
interactions within the drug and the polymer 
complex. 
Percentage of Drug Entrapment Efficiency 
After niosomal preparation the percentage of 
entrapment efficiency of ethambutol HCl was found 
to be range from 72.26 to 86.73 %. It was observed 
thatwhen increased the lipid concentration caused by 
higher entrapment efficiency.Moreover, higher drug 
loading lowered the percentage of entrapment and 
encapsulation, which shown the wastage of drug 
during the micro encapsulation process.The % drug 
entrapment efficiency of the prepared Niosomes 
formulations are shown in table no.6   and displayed 
in figure no.8 
Particle size Analysis:  
Prepared niosomal mean particle sizefound that 
200nm to 300nm. Actually the mean size was 
influenced by the concentration of lipid used in the 
formulation. As the volume of water varies, niosomes 
deformed to nonspheral shape and even broken and 
the effect of stirring speed was also observed for all 
formulations,as the stirring speed was increased there 
is decrease in average particle sizedue to high stress 
developed at the interface caused by creation of new 
surfaces which were stabilized by amphiphiles 
resulting in smaller particle size distribution. Mean 
particle size of all formulations are given in the table 
no. 6 and its graphical representation shown in the 
figure no. 9. 
Table 6: Percentage of Drug entrapment efficiency, Particle size of niosomal preparation of ethambutol HCl. 
 
Formulation code %Drug entrapment efficiency* Particle size* (nm) 
F1 86.73 227.9 
F2 74.58 227.3 
F3 77.27 407.0 
F4 81.92 202.4 
F5 85.43 214.3 
F6 79.53 212.5 
F7 76.51 280.6 
F8 72.26 201.3 
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Fig 8:  % of Entrapment efficiency (E.E) of different Formulations 
 
 
Fig 9:  Average particle size of Formulations 
 
 
Shape and Surface Morphology:  
Morphology of the niosomal preparation was 
investigated by scanning electron microscopy and 
were spherical & irregular and their surface was 
smooth and devoid of cracks giving them good in 
appearance. In general, the Niosomes were well 
formed and in shape. The obtained SEM data are 
shown in figure no.10. 
Fig10: SEM images of Ethambutol HCl loaded Niosomes 
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In Vitro Drug release of niosome of Ethambutol 
HCl using Dialysis bag method: 
In vitro drug release studies of all the niosomal 
formulations were carried out in a phosphate buffer 
pH 7.4 using dialysis membrane. The study was 
performed for 12 hrs, and cumulative drug release 
(CDR) was calculated for different time intervals. 
The formulations F1, F2, F3, F4, F5, F6, F7, and F8 
have shown the drug release of 85.50%, 91%, 
88.80%, 87.70%, 84.41%, 86.61%, 88.80% and 
92.09% respectively after 12 hrs. The drug release 
profile formulation F1 table no. 7 shown drug release 
kinetic data and cumulative drug release profile of all 
prepared formulations are shown in table no. 8 
It was observed from the formulations that, “the drug 
release profile slightly increases as the concentration 
of lipid of formulation increases. The data of 
dissolution study indicates that the drug release from 
niosome was slow and sustained up to 12hrs”. 
Table 7: In vitro Drug release profile of F1 formulation 
Time(
min) 
Sq. root 
Time 
Log time  
Abs 
 
CDR 
 
% 
C D R* 
Log % CDR % Drug    
retained 
Log % drug 
retained 
0 0 0 0 0 0 0 100 2 
5 2.236 0.698 0.002 2.18 2.18 0.33 97.82 1.99 
   15 3.872 1.176 0.004 4.37 4.37 0.64 95.63 1.98 
30 5.477 1.477 0.007 7.67 7.67 0.88 92.33 1.96 
45 6.708 1.653 0.010 10.96 10.96 1.03 89.04 1.93 
60 7.745 1.778 0.013 14.24 14.24 1.15 85.76 1.93 
90 9.486 1.954 0.018 19.72 19.72 1.29 80.28 1.90 
120 10.954 2.079 0.022 24.11 24.11 1.38 75.89 1.88 
180 13.416 2.255 0.036 39.46 39.46 1.59 60.54 1.78 
240 15.491 2.380 0.042 46.04 46.04 1.66 53.96 1.73 
300 17.320 2.477 0.049 53.72 53.72 1.73 46.28 1.66 
360 18.973 2.556 0.055 60.29 60.29 1.78 39.71 1.59 
420 20.493 2.623 0.061 64.41 64.41 1.80 35.59 1.55 
480 21.908 2.681 0.065 71.26 71.26 1.85 28.74 1.45 
540 23.237 2.732 0.068 74.54 74.54 1.87 25.46 1.40 
600 24.494 2.778 0.071 77.83 77.83 1.89 22.17 1.34 
660 25.690 2.819 0.074 81.13 81.13 1.90 18.87 1.27 
720 26.832 2.857 0.078 85.50 85.50 1.93 14.50 1.16 
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Table 8: In vitro Drug release profile of F1 to F8 formulation 
             * Cumulative Drug Release 
 
 
 
 
 
Time 
(min) 
Sq. 
root 
Time 
Log 
time 
F1 F2 F3 F4 F5 F6 F7 F8 
Abs  
CDR* 
(%CD
R) 
 
Abs CDR*  
(% 
CDR) 
 
Abs  
CDR
* (% 
CDR
) 
 
Abs  
CDR* 
(% 
CDR) 
 
Abs  
CDR* 
(% 
CDR) 
 
Abs  
CDR* 
(% 
CDR) 
 
Abs  
CDR* 
(% 
CDR) 
 
Abs  
CDR*  
(% 
CDR) 
 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
5 2.236 0.698 0.002 2.18 0.003 3.28 0.002 2.18 0.002 2.18 0.001 1.09 0.002 2.18 0.003 3.28 0.004 4.37 
   15 3.872 1.176 0.004 4.37 0.007 7.67 0.005 5.48 0.004 4.37 0.002 2.18 0.002 2.18 0.003 3.28 0.004 4.37 
30 5.477 1.477 0.007 7.67 0.010 10.96 0.009 9.85 0.007 7.67    
0.005   
5.48 0.005 5.48 0.008 8.76 0.011 12.05 
45 6.708 1.653 0.010 10.96 0.015 16.44 0.014 15.34 0.013 14.24 0.012 13.23 0.012 13.15 0.010 10.96 0.013 14.24 
60 7.745 1.778 0.013 14.24 0.018 19.72 0.017 18.63 0.015 16.44 0.014 15.34 0.013 14.24 0.014 15.34 0.016 17.53 
90 9.486 1.954 0.018 19.72 0.021 23.02 0.024 26.30 0.023 25.20 0.020 21.92 0.018 19.72 0.020 21.92 0.022 24.11 
120 10.95
4 
2.079 0.022 24.11 0.026 28.50 0.029 31.78 0.026 28.50 0.024 26.30 0.022    
24.11 
0.024    
26.30 
0.027    
29.59 
180 13.41
6 
2.255 0.036 39.46 0.035 38.37 0.038 41.65 0.037 40.56 0.035 38.37 0.036 39.46 0.038 41.65 0.039 42.74 
240 15.49
1 
2.380 0.042 46.04 0.043 47.13 0.046 50.42 0.046 50.42 0.040 43.85 0.041 44.94 0.043 47.13 0.047 51.52 
300 17.32
0 
2.477 0.049 53.72 0.050 54.81 0.053 58.09 0.052 57.00 0.050 54.81 0.052 57.00 0.054 59.20 0.056 61.39 
360 18.97
3 
2.556 0.055 60.29 0.054 59.20 0.059 64.68 0.060 65.78 0.058 63.58 0.060 65.78 0.062 68.00 0.065 71.26 
420 20.49
3 
2.623 0.061 64.41 0.062 68.00 0.064 70.66 0.054 70.16 0.060 65.78 0.062 68.00 0.065 71.26 0.070 76.74 
480 21.90
8 
2.681 0.065 71.26 0.064 70.66 0.069 75.64 0.068 74.54 0.065 71.26 0.066 71.72 0.068    
74.54 
0.073 80.02 
540 23.23
7 
2.732 0.068 74.54 0.066 71.72 0.071 77.83 0.070 76.74 0.070 76.74 0.071 77.83 0.074 81.13 0.081 88.80 
600 24.49
4 
2.778 0.071 77.83 0.074 81.13 0.076 83.31 0.074 81.13 0.072 78.93 0.075 82.25 0.077 84.41 0.082 89.89 
660 25.69
0 
2.819 0.074 81.13 0.079 86.61 0.078 85.50 0.079 86.61 0.075 82.22 0.077 84.41 0.079 86.61 0.083 91.00 
720 26.83
2 
2.857 0.078 85.50 0.083 91.00 0.081 88.80 0.080 87.70 0.077 84.41 0.079 86.61 0.081 88.80 0.084 92.09 
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Zero order kinetic Model 
Fig 11: % Cumulative Drug Release v/S. Time. 
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First order kinetic model 
Fig 12: Log % Cumulative Drug Remaining v/s. Time. 
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Higuchi’s classical diffusion model 
Fig 13: % Cumulative Drug Released v/s. Square Root of Time. 
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Drug release kinetic data for niosome formulations: 
To find out exact mechanism of drug elease from 
niosomes, data was fitted in three different kinetic 
models and various equations were used, such as zero-
order rate equation, first-order and Higuchi’s Classical 
Diffusion model.   
Zero-order rate equation describes the release from 
system is independent of the concentration of the 
dissolved content. The first-order equation describes the 
release rate from the systems is dependent on the 
concentration of the dissolving species. Higuchi’s 
Classical Diffusion model describes the release from 
system where drug solution is dispersed in insoluble 
matrix, and the rate of drug release is related to the rate 
of diffusion. Thus found that, the data obtained from in 
vitro drug release studies were fitted to zero-order,  
first-order and Higuchi’s equations and is 
represented in figure no.11, 12 and 13. After 
performing statistical analysis for release study 
data the coefficient of correlation was found to 
favor zero order kinetics. 
For studying the release kinetics, all formulations 
are fitted in the mathematical models.  In order to 
describe the kinetics of the release process of drug 
in all formulations,  
The drug release data obtained of niosome 
formulations were plotted in the following modes 
of data treatment. And kinetic modeling of drug 
release data shown in table no. 9 
Zero Order Kinetics: - Time v/S. % Cumulative Drug Release.  
First Order Kinetics: - Time v/S. Log % Cumulative Drug Remaining.  
Higuchi Plot: - Square Root of Time v/S. % Cumulative Drug Released 
 
Table 9: Kinetic modeling of drug release from Niosomes 
Formulation 
code 
Zero order First order 
 
Higuchi’s equation 
R2 Slope R2 Slope R2 Slope 
F1 0.9563 0.1219 0.9978 -0.0011 0.9873 3.536 
F2 0.9663 0.1217 0.9596 -0.0012 0.9922 3.520 
F3 O.9439 0.1246 0.9979 -0.0012 0.9936 3.651 
F4 0.9448 0.1256 0.9966 -0.0012 0.9900 3.671 
F5 0.9496 0.1233 0.9964 -0.0011 0.9874 3.590 
F6 0.9513 0.1276 0.9967 -0.0012 0.9831 3.705 
F7 0.9480 0.1302 0.9975 -0.0013 0.9842 3.789 
F8 0.9455 0.1357 0.9894 -0.0016 0.9852 3.956 
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Values for regressions coefficient shown in table no.9 for 
different kinetic models. From the results it is cleared that 
the drug release mechanism from the formulations was 
found to follow First order kinetics. The dissolution 
process is purely defined by the total concentration of the 
drug present in the developed formulation, indicating that 
the total drug payloads play an important role in the 
release profile. 
CONCLUSION: 
In this work an attempt was made to prepared a vesicular 
drug delivery system in the form of niosomes for an 
antitubercular drug ethambutol HCl, for deliver at proper 
site to achieve and maintain the desired drug concentration 
for sustained activity and thus prevent repeated 
dose of drug which was proved by in vitro release 
study data, that all the formulations followed first order 
kinetic model. This implies that developed formulations 
have a potential to deliver the drug in controlled release 
manner.  
However, TB is difficult to treat, due to the unusual 
structure and chemical composition of the mycobacterium 
cell wall, which makes many antibiotics ineffective, TB 
requires much longer periods of treatment (around 6 to 24 
months) to entirely eliminate mycobacteria from the body. 
According to research found that almost all antitubercular 
drugs shows poor absorption in presence of food, need of 
multidrug regimens, poor patient compliance. These 
problems could possibly be prevented by shielding the 
drug from the extracellular environment by means of a 
lipid coating i.e. niosomes. The lipid coating is 
destabilized upon interaction with cells of the target site 
resulting in the local release of the encapsulated drug.  
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